Lipid management in cardiovascular disease prevention guidelines: Strategies and tactics for implementation

      Abstract

      Despite the widespread dissemination of clinical practice guidelines on the prevention and treatment of cardiovascular disease (CVD), CVD causes one third of deaths worldwide and almost half of all deaths in the developed world. It is therefore likely that, although some aspects of CVD management have improved, there is still a significant shortfall between what is known about CVD prevention and what is put into action.
      Twenty-one experts in the field of CVD from around the world attended a focus panel meeting in Marlow-on-Thames, UK (see acknowledgements for a list of meeting participants). These experts were invited to discuss practical strategies and tactics for overcoming barriers to the implementation of guidelines on CVD prevention, and lipid management in particular. This article reviews and updates the key topics presented during the course of the meeting, captures the essence of the group discussions, and summarizes the meeting outcomes.
      The participants concluded that initial efforts to implement CVD prevention guidelines more effectively are best directed at high-risk patients who have already been identified. Once current patients achieve their targets, more attention can be paid to finding untreated patients at risk. Recommendations from the expert panel included:
      • Harmonize guidelines; focus on common areas of consensus rather than state-of-the-art science
      • Remove the boundary between primary and secondary prevention and focus on level of overall risk
      • Help policy makers understand the different components of CVD
      • Include professional societies from different specialties in guideline development and implementation, to increase ownership and decrease fragmentation of guideline committees.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001;285:2486–97.

        • De Backer G.
        • Ambrosioni E.
        • Borch-Johnsen K.
        • et al.
        European guidelines on cardiovascular disease prevention in clinical practice, third joint task force of European and other societies on cardiovascular disease prevention in clinical practice.
        Eur J Cardiovasc Prev Rehabil. 2003; 10: S1-S10
        • Smith S.C.
        • Jackson R.
        • Pearson T.A.
        • et al.
        Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Foundation.
        Circulation. 2004; 109: 3112-3121
        • Grundy S.M.
        • Cleeman J.I.
        • Merz C.N.
        • et al.
        Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
        Circulation. 2004; 110: 227-239
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • et al.
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435
        • Erhardt L.R.
        • Pearson T.A.
        • Bruckert E.
        • et al.
        Guidelines and their implementation: a discussion document focused on the best approaches to drive improvement.
        Vasc Dis Prev. 2004; 1: 167-174
      2. World Health Organization. Global burden of disease estimates 2002. Available at: http://www.who.int/healthinfo/statistics/gbdwhosubregionmortality2002.xls. Accessed October 14, 2004.

        • EUROASPIRE
        • A European society of cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE study group
        European action on secondary prevention through intervention to reduce events.
        Eur Heart J. 1997; 18: 1569-1582
        • EUROASPIRE II study group
        Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II euro heart survey programme.
        Eur Heart J. 2001; 22: 554-572
        • Pyorala K.
        • De Backer G.
        • Graham I.
        • Poole-Wilson P.
        • Wood D.
        Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European society of cardiology, European atherosclerosis society and European society of hypertension.
        Eur Heart J. 1994; 15: 1300-1331
      3. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J 1998;19:1434–503.

      4. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II group. European action on secondary prevention by intervention to reduce events. Lancet 2001;357:995–1001.

        • Vale M.J.
        • Jelinek M.V.
        • Best J.D.
        • COACH study group
        How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996–1998 versus 1999–2000.
        Med J Aust. 2002; 176: 211-215
        • Pearson T.A.
        • Laurora I.
        • Chu H.
        • Kafonek S.
        The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.
        Arch Intern Med. 2000; 160: 459-467
      5. Leiter L, Betteridge D.J. The AUDIT study: a worldwide survey of physician attitudes about diabetic dyslipidemia. Poster presented at: American diabetes association 64th annual scientific sessions; June 4–8, 2004. Orlando, FL.

        • Hobbs F.D.
        • Erhardt L.
        Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the reassessing European attitudes about cardiovascular treatment (REACT) survey.
        Fam Pract. 2002; 19: 596-604
        • Erhardt L.
        • Hobbs F.D.
        Public perceptions of cardiovascular risk in five European countries: the REACT survey.
        Int J Clin Pract. 2002; 56: 638-644
        • Cabana M.D.
        • Rand C.S.
        • Powe N.R.
        • et al.
        Why don’t physicians follow clinical practice guidelines? A framework for improvement.
        JAMA. 1999; 282: 1458-1465
        • Colhoun H.M.
        • Betteridge D.J.
        • Durrington P.N.
        • et al.
        Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial.
        Lancet. 2004; 364: 685-696
        • Consoli S.M.
        • Bruckert B.E.
        Educational level has a major impact on the representations of cholesterol: a study in 1579 hypercholesterolemic patients.
        Prev Med. 2004; 38: 323-329
      6. Department of Health. The National service framework for coronary heart disease. Winning the war on heart disease: progress report 2004. London: Department of health publications; 2004. Available at: www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/CoronaryHeartDisease/fs/en. Accessed May 4, 2004.

        • Yan A.T.
        • Tan M.
        • Fitchett D.
        • et al.
        One-year outcome of patients after acute coronary syndromes (from the Canadian acute coronary syndromes registry).
        Am J Cardiol. 2004; 94: 25-29
        • Schwartz G.G.
        • Olsson A.G.
        • Ezekowitz M.D.
        • et al.
        Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
        JAMA. 2001; 285: 1711-1718
        • Fitchett D.H.
        • Leiter L.A.
        • Tardif J.C.
        • Goodman S.G.
        • Langer A.
        Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?.
        Can J Cardiol. 2005; 21: 85-90
        • Backlund L.
        How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients?.
        Prim Health Care Res Dev. 2004; 5: 145-152
        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • et al.
        The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report.
        JAMA. 2003; 289: 2560-2572
        • Emberson J.R.
        • Whincup P.H.
        • Morris R.W.
        • Walker M.
        Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias.
        Eur Heart J. 2003; 24: 1719-1726
        • Nissen S.
        • Tuzcu E.M.
        • Libby P.
        • et al.
        Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial.
        JAMA. 2004; 292: 2217-2226
      7. World Health Organization. Integrated management of cardiovascular risk: report of a WHO meeting, Geneva, 9–12 July 2002. Geneva: World Health Organization; 2002. ISBN 92 4 156224 2.